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3Abstract
Two decades after its discovery the human immunodeficiency virus (HIV) is still 
spreading worldwide and killing millions. There are twenty-four drugs formally 
approved for HIV currently on the market, but major side effects as well as the 
emergence of HIV strains showing single or multiple resistances to current 
drug-therapy are causes for concern. Furthermore, these drugs target only 4 steps 
of the viral cycle, hence the urgent need for new drugs and also new targets. In 
order to tackle this problem, we have devised a cell based assay using lentiviral 
particles to look for post-entry inhibitors of HIV-1. We report here the assay 
development, validation as well as confirmation of the hits using both wild-type and 
drug-resistant HIV-1 viruses. The screening was performed on an original library, 
rich in natural compounds and pure molecules from Traditional Chinese Medicine 
pharmacopoeia, which had never been screened for anti-HIV activity. The identified 
hits belong to four chemical sub-families that appear to be all non nucleoside 
reverse transcriptase inhibitors. Secondary tests with live viruses showed that there 
was good agreement with pseudotyped particles, confirming the validity of this 
approach for high throughput drug screens. This assay will be a useful tool that can 
be easily adapted to screen for inhibitors of viral entry.
Keywords: HIV; pseudotyped lentiviral particles; high-throughput screening; HTS; 
cocktail library; NNRTi;
41 Introduction
More than two decades after the identification of Human Immunodeficiency Virus 
(HIV) as the causative agent of AIDS, the disease remains a huge concern for 
global public health. In 2007 it was estimated that 33.2 million people worldwide
were living with HIV, 2.5 millions became newly infected and 2.1 millions of patients
died of AIDS (UNAIDS/WHO, 2007). Although the HIV prevalence rate is still low, 
South-East Asia is one of the regions where the HIV/AIDS epidemic is most rapidly 
growing. AIDS is considered a serious threat to public health and safety in China, 
and also a strategic issue for social stability, economic growth, national prosperity 
and security. Furthermore, an increasing portion of patients with HIV cannot use 
currently approved anti-HIV drugs due to the adverse effects and because of the 
emergence of HIV strains showing single or multiple resistances to current 
drug-therapy (Yeni, 2006).
To date, antivirals are the only therapeutic option to manage HIV as the recently 
publicized failure of a Phase II vaccine trial pushes back the prospects of an 
effective prophylactic vaccine (Cohen, 2007a, 2007b). Despite 29 commercially 
available drugs (Flexner, 2008), these molecules belong to only seven therapeutic 
classes and target only 1 cellular and 4 viral proteins: the cellular co-receptor CCR5 
(Maraviroc), the surface envelope glycoprotein gp160 (the peptide Enfuvirtide), 
reverse transcriptase (10 nucleoside and 3 nucleotide analogs; 3 non-nucleoside
analogs), protease (10 peptidomimetic) and integrase (Raltegravir). Due to 
increasing resistance to existing therapies, HIV drug development is searching for 
new agents in classes that do not share cross-resistance, as well as for new 
classes of drugs that would either not be affected by such resistance or would act 
on new targets (Sension, 2007). Because of resistance, available drugs are no 
longer used as monotherapy (Pillay et al., 2000) but, rather, in a combination of 
drugs targeting different steps in the viral life cycle, termed highly active 
5antiretroviral therapy (HAART).
Altogether, the emergence of drug resistant HIV strains, the important side effects 
of current drugs and their high cost underscore the importance for the 
developments of new treatments to fight the AIDS pandemic. The mechanism of 
HIV replication involves a complex interplay between virus and host cells, from cell 
attachment to release of newly assembled virions (Sorin and Kalpana, 2006). 
Therefore, every single step is potentially a potential target for drug discovery
(Bennasser et al. 2007; Esté and Telenti, 2007; Faustino et al. 2007; Liu et al. 2007; 
Salzwedel et al. 2007; Zeinalipour-Loizidou et al. 2007).
We have taken advantage of high-throughput screening (HTS) technology using a 
cell-based assay to look for new inhibitors of post-entry events in HIV infection. 
Identification of HIV antiviral molecules from natural products has been pursued 
with success and has been extensively reviewed by De Clercq (2000). The 
screening was performed on an original library, rich in natural compounds and pure 
molecules from the Traditional Chinese Medicine (TCM) pharmacopoeia, which
had never been screened for anti-HIV activity. Here, we describe an efficient and 
cost-effective antiviral screening system that utilizes pseudotyped viruses for 
primary antiretroviral screening.
62 Materials and methods
2.1 Cells
MT4 cells were cultured in RPMI 1640 with Glutamax (Invitrogen) supplemented 
with 10% Fetal Calf Serum (FCS) (Sigma) and penicillin-streptomycin (100 IU/ml 
each, Sigma). HeLa cells (P4 and P4C5 clones; Maréchal et al., 1998) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax
supplemented with 10% FCS and penicillin-streptomycin. P4 and P4C5 HeLa cells 
are CD4+ carrying an HIV long terminal repeat (LTR) lacZ reporter cassette; they
express either CXCR4 (P4 cells), or CXCR4 and CCR5 (P4C5 cells) surface 
co-receptors for the envelope glycoprotein gp160.
2.2 Design and production of pseudotyped virus
The pseudotyped virus was engineered from two plasmids, one coding for 
envelope, and the second for backbone and reporter gene. The glycoprotein G 
from Vesicular Stomatitis Virus (VSV-G) was selected as the envelope protein 
because it allows the infection of a very wide range of cell types from a variety of 
organisms (Burns et al., 1993). VSV-G interacts with a phospholipid component of 
the cell surface membrane and mediates viral entry by membrane fusion
(Mastromarino et al., 1987). Furthermore, VSV-G pseudotyped viruses have 
already been shown to provide high titers (Burns et al., 1993). Because the target 
of our screening was HIV-1 replication, the polyprotein sequence from proviral 
vector pNL4.3-Luc E-, with env deleted, was used as the backbone and engineered 
to express the firefly luciferase gene (Connor et al., 1995), which was selected over 
fluorescent reporters for the larger working range (4-log) and greater sensitivity it 
allows (Olesen et al., 2000; data not shown). These virions are valuable reagents 
for antiviral screening since they allow a reduction in viral RNA replication to be 
measured by direct enzymatic quantification of luciferase in the cell lysate using a 
7simple add-and-read type of cell-based assay.
Production of these pseudotyped viruses with a single infectious cycle was based 
on a previously published design (Naldini et al., 1996), by co-transfecting HEK293T 
cells (”producer cells“) with a plasmid expressing the envelope protein (VSV-G) and 
a plasmid containing the modified proviral genome of HIV. In the producer cells only 
the transcript from the proviral plasmid was packaged into the capsid due to the 
presence of the packaging signal in the plasmid sequence. During the budding 
process, capsids were enveloped by the VSV-G proteins expressed on the cell 
surface prior to their release into the medium. A similar procedure was applied to 
produce two other pseudoptypes: a first one in which the VSV-G gene is replaced 
by the HIV envelope HxB2; and a second one in which the Enhanced Green 
Fluorescent Protein (GFP) was used as the reporter gene instead of luciferase.
2.3 Compounds and library
3’-Azido-3’-deoxythymidine (AZT) was purchased from Sigma. Compounds were
provided by the National Centre for Drug Screening (NCDS, Shanghai, China) 
associated with the Shanghai Institute of Materia Medica (SIMM). This national 
library is composed of more than 100 000 samples, 70% of which are pure and 
chemically defined compounds, whereas the remaining 30% are extracts from 
either micro-organisms or TCM formulation. 10% of the pure compounds are from 
natural sources and 2-3000 are pure compounds from TCM, the largest such 
collection in the world. The origin of the pure synthetic compounds is either from 
commercial libraries (ensuring a diversity of templates) or from Chinese chemical 
laboratories. All pure compounds respect Lipinski rules for drugability. Together, 
several hundred scaffolds are represented, covering a large part of the chemical 
space. In this project we decided to screen a sub-library of 48 000 pure compounds 
that was already formatted in orthogonal cocktail.
82.4 Orthogonal cocktail strategy
Compound library samples were orthogonally pooled as mixtures of 10 compounds 
per well at 2 µg/mL each, with duplicate representation for each compound. This 
bidirectional orthogonal pooling strategy allows for greater screening efficiency and 
throughput for large compound libraries. The pooling was prepared as follows. One 
hundred plates (96-wells), containing a single compound/well (“source plates”),
were laid out in a 10 x 10 grid. Orthogonal cocktails were then made by mixing into 
one well of the “cocktail plate” each compound from the same well of 10 “source 
plates” (Figure 1). Each compound was represented twice in 20 “cocktail plates”, 
each time with 9 different sister compounds. Therefore, because the mixture were
made orthogonally, each compound was present in two orthogonal cocktail wells 
and, conversely, two orthogonal cocktail wells have only one compound in common. 
Assuming that the chance to encounter two positive compounds within the same 
cocktail is negligible, it is postulated that a high activity measured in two orthogonal 
wells is most likely caused by the one compound in common.
2.5 Primary screening
Test compounds were prepared from initial dimethyl sulfoxide (DMSO) stocks and 
plated as described above, 80 cocktails per plate. Low passage HeLa-P4 cells 
were then trypsinized, counted and seeded at a final concentration of 104 cells/well. 
Plates were left 1 hour at room temperature before being placed overnight in a CO2
incubator in order to avoid the edge effect (Lundholt et al., 2003). The following day, 
samples and controls (AZT) were then added with an automatic liquid handler (FX 
from Beckman-Coulter). Finally, the pseudotyped virus, thawed and diluted 
immediately prior to use in cell culture medium, was added under a BSL-2 hood 
using Hydra (Thermo Fisher Scientific). The final concentration of DMSO in all wells 
was maintained at 2%. The plates were incubated at 37°C in a humidified CO2
incubator for 48 hours. Steady-glow substrate (Promega) was added directly to 
9each well with the FX automatic liquid handler and cell lysis was allowed to proceed 
in the dark for 20 minutes. Luciferase activity was measured using the Envision 
microplate luminometer (Perkin Elmer).
2.6 Primary cytotoxicity screening
The cytotoxicity of “active” compounds identified during the primary screening was 
evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay at the end of the incubation period (Mosmann, 1983). Briefly, HeLa-P4 cells 
(104 cells/well, 50 µL) were plated in 96-well microtiter plates and incubated for 18 
hours at 37°C (humidified atmosphere, 5% CO2), followed by a second incubation 
for 48 hours in the presence of the test compounds. MTT (20 µl at 5 mg/mL) was 
added to each well and incubated for 3 hours at 37°C after which medium was 
replaced by 100 μL of DMSO. The plates were placed on a shaker for 10 min at 
room temperature and the OD550 measured using a SpectraMAX340 microplate 
reader (Molecular Devices) with a reference wavelength at 690 nm.
2.7 Time of addition study
MT4 cells were seeded at 104 cells/well in 50 μL of RPMI 1640 supplemented with 
Glutamax and 10% FCS, left for rest one hour at room temperature to avoid the 
edge effect and placed overnight into incubator at 37°C. The following day, cells 
were infected with 50 μL of pseudoparticles; each compound as well as AZT was 
added at a final concentration of 4 μM at different time points and up to 30 hours, 
with t=0 defined as the time of pseudoparticle addition. Sample solutions were kept 
at 4°C. At 48 hours post infection, cells were lysed with 100 μL of steady glow 
luciferase substrate and bioluminescence was measured after further 20 min 
incubation within the microbeta plate reader (Perkin Elmer).
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2.8 In-Silico docking
In silico docking of selected hits in the reverse transcriptase structure crystallized 
with the NNRTI Nevirapine (PDB accession number 1FKP) was performed with the 
program Arguslab 4.0.1 from Mark Thompson and Planaria Software LLC (website). 
Docking parameters used were as follows: ArgusDock for the docking engine; 
Binding site Bounding Box settings to cover the entire reverse transcriptase protein 
(grid resolution 0.4 Ang.); Calculation type: Dock; Ligand: flexible.
2.9 HIV-1 virus infection
The production and use of wild-type (WT) and mutant HIV have been previously 
described (Petit et al., 2001). The various drug-resistant strains were derived from 
NL4.3, a CXCR4-tropic HIV strain (Moore et al., 2004), and were a kind gift of 
Fabrizio Mammano (Institut Pasteur, Paris) and Elisabeth Dam (INSERM U552, 
Hôpital Bichat, Paris): NL4.3XCS MDR 151, which is resistant to various nucleoside 
analogues (Zidovudine (AZT), Stavudine (d4T), Didanosine (ddI)); NL4.3XCS 
41-215, which is AZT resistant; NL4.3XCS M184V, which is Lamivudine (3TC)
resistant; NL4.3XCS K103N, which is Nevirapine (NVP) resistant; and NL4.3XCS 
188L-190A, which is highly resistant to NVP (de la Carrière et al., 1999).
For single-cycle HIV infection experiments, P4 or P4C5 cells carrying an HIV long 
terminal repeat (LTR) lacZ reporter cassette (1.5x104 cells/well, in triplicates), were 
pre-incubated 30 minutes with the indicated drugs, and then exposed to the 
different virus stocks. Viral input, quantified as ng of p24 (Sol-Foulon et al., 2007),
was either 1 ng or 5 ng of p24/well (equivalent to an MOI of ~0.02 or MOI ~0.1
respectively, see following section 2.10 for detail on MOI calculation). Cells 
were briefly centrifuged (5 minutes at 1200 rpm), maintained in the presence of 
drugs for 48 hours and then ß-galactosidase activity was measured in a 
colorimetric CPRG assay at an OD540 (Eustice et al., 1991).
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2.10 Calculation of the MOI
Titration of HIV was performed as described (Schwartz et al., 1995). Briefly, 
virus stocks were assessed for Gag p24 concentration using a commercial 
antigen capture ELISA (Du Pont de Nemours-NEN, HIV-1 p24 Core Profile 
ELISA), according to the manufacturer's instructions. Infectivity of viral 
supernatants was determined using P4 cells. These HeLa-CD4 cells carry the 
bacterial LacZ gene under the control of the HIV-1 LTR, and cytoplasmic 
accumulation of ß-galactosidase is strictly dependent on the presence of Tat. 
One day before infection, 1.2x105 cells/well were seeded in a 24-well plate. 
The following day, the medium was replaced with 500 µl of diluted virus stock 
(serial dilutions in culture medium from 100 to 0.1 µl) in the presence of 20 
µg/ml of DEAE-Dextran. After 3 hours of incubation with the viral samples, 1 
ml of fresh medium was added. After 24-hour incubation at 37°C, cells were 
fixed and ß-galactosidase activity was revealed with 
5-bromo-4-chloro-3-indoyl-ß-D-galactopyranoside (X-Gal). Blue cells foci 
were scored under a binocular microscope. Experiments were performed in 
triplicate or in duplicate, and variations for each viral dilution were less than 
10%. A background level of 5 to 15 blue cells was detected in wells of 
uninfected cells and was subtracted from the number of blue cells scored for 
experimental points. This assay was reproducible and generated linear 
values when serial virus dilutions were used. We generally obtain 500-1000 
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blue foci per ng of p24. Therefore, in 96-well plates seeded with 1.5x104 cells 
per well, infection with 1 and 5 ng of p24 per well corresponds to an MOI of 
0.02 and 0.1, respectively.
2.11 Data analysis
Assay quality and robustness were determined during the optimization as well as 
during the screening by calculation of the statistical parameters Z (and Z’) 
introduced by Zhang (Zhang et al., 1999). To determine the effects of the 
compounds in the assay, data were compared to a cut-off value defined as mean of 
the control and inactive compound (all except outliners) minus twice their standard 
deviation using homemade macros in Excel (Microsoft). Because of the orthogonal 
cocktail strategy, we assessed for each well the concordance of inhibition (below 
the set cut-off limit) in paired “cocktail plates”. Concordant wells represent, 
therefore, a “positive” that needs to be subsequently confirmed as individual 
compound to become an “active” molecule.
Estimates for IC50 were obtained using "drc" package (Ritz & Streibig, 2005) for "R”
(http://www.R-project.org). Weibull and Logistic regression with 3 or 4 parameters 
(W3, W4, L3 and L4) were adjusted, and a lack-of-fit test performed, comparing the 
non-linear regression model to a more general one-way ANOVA model. 
Non-significant values (p>0.01) for this test suggest the model provide comparable 
performance to the one-way ANOVA. In the next step comparisons between nested 
models were also conducted via ANOVA, with significant values (p<0.01) pointing 
evidence toward more complex models. Finally, all adjusted curves were visually 
inspected for ultimate decision when statistics test do not provide sufficient 
evidence to favor any model.
13
3 Results
3.1 Assay development and optimization
In this report, we describe the development, validation and use of pseudotyped 
lentiviral particles for in vitro cell based screening of antiviral compounds. Several 
experimental parameters were found to affect the readout and were optimized 
including cell type and number, concentrations of DMSO and pseudoparticles, 
timing of each step (reagent additions, infection/incubation, endpoint 
measurement), different types of luciferase substrates as well as protocol of 
compound delivery (Figure 2).
3.2 Assay automation and validation for HTS
While the development and optimization of the assay were done manually,
screening of large number of compounds requires an automated process. During 
the validation step of the assay on the automated platform we observed an 
unexpectedly high coefficient of variation between replicates. This variation could 
be attributed mainly to the step of adding 2µL of compounds in DMSO to 98 µL of 
medium. To optimize this step we tested the accuracy of sample delivery with a 
DMSO solution containing 4-nitro-phenylamine by direct reading of absorbance 
(max=412 nm). A significant reduction of the coefficient of variation from 8% to 
below 2% was achieved by including in the protocol an additional 20µL washing
step to ensure proper recover of the drug from the tip while mixing the sample (data 
not shown). As the compounds were formatted in 80 cocktails per plate in columns 
2 to 11, controls (DMSO only and AZT in DMSO) were added for the assay to each 
side (columns 1 and 12) with 96-tips head filled only with these two columns. 
Therefore, we also checked that this procedure did not affect the reproducibility of 
dispensing samples (data not shown). The assay was then validated on a 
representative subset of the library (800 compounds) tested three times. The 
statistical parameters of the assay indicated that both quality (Z’=0.72, Z=0.60) as 
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well as reproducibility given by the intra-plate and inter-plates coefficients of 
variation (CVintra=2.1%, CVinter=3.4%) were adequate.
3.3 Primary screening
We have used this assay for the screening of a library of 48 000 pure compounds,
formatted in orthogonal cocktails. As illustrated in Figure 3 for one of the six
batches of 20 plates of orthogonal cocktails, most compounds did not show any 
inhibitory activity. A sample was considered positive for inhibitory activity when both 
values from Y- and X-plates fell below the cut-off (defined as the average (m) minus 
two standard deviations (SD): m-2SD). A total of 63 molecules were confirmed in 
singlet and identified as active, 32 of which were excluded as toxic by the MTT 
assay. Therefore, a total of 31 compounds, which showed no cytotoxicity at 
concentrations as high as 2 μg/ml (range 4-9 μM), represent primary hits (hit rate: 
0.06%). Given the inhibitory effect measured for these molecules (Supplementary 
Materials, Figure S1), this hit rate is comparable to that observed by Noah et al. 
(2007) when they used a cutoff threshold of 50% inhibition.
3.4 Analysis of the hits
To exclude that the observed inhibition was due to a trivial interference with the 
entry step mediated by VSV-G envelope protein, or with the enzymatic activity of 
the luciferase reporter gene, we used the same lentiviral backbone pseudotyped
with either HxB2 envelope from HIV or containing GFP as the reporter gene, 
respectively. These two swaps (HIV-HxB2 for VSV-G and GFP for luciferase) did
not modify the inhibitory profile, indicating that the hits affected at least one
post-entry step of the HIV life cycle up to the translation of reporter gene. 
Furthermore, these hits were not active against Semliki Forest Virus (SFV, an 
alphavirus), thus suggesting some degree of specificity (Figure 4). The calculated 
IC50 of the drugs in these assays with HIV-HxB2-HIV(Luc), VSV-G-HIV(Luc) and 
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VSV-G-HIV(GFP) was generally in the sub-micromolar range (Table 2). The 
apparent higher IC50 measured with live wild type virus compared with 
HxB2-HIV(Luc) pseudovirus is due to the fact that the virus has several rounds of 
infection/replication, whereas the replication-deficient pseudoparticle, by definition,
can only infect once. Furthermore, in the live virus assay, fusion between infected 
and non infected cells can be observed; this favors the passage of tat protein from 
one cell to the other leading to LTR transactivation on non infected cells. This 
exponential mechanism could explain why a higher drug concentration is required 
with live virus. Finally, in order to gain some insight into the specific step that was 
targeted, we performed time of addition experiments. Our results show that the time 
course of neutralization followed that induced by AZT, suggesting either an 
inhibition of the reverse transcriptase or of a concomitant step (Figure 5).
We next examined the general structure of the hits and identified four sub-families 
derived from a common template that comprises a first aryl with preferentially 
electron-withdrawal groups, attached via a linker of variable length and flexibility to 
another aryl bearing preferentially electron-rich groups (Figure 6). For the first
family, the linker can be described as a heterocycle (mainly, but not only, tetrazole 
groups) substituted with an electron-rich group (e.g. thioacetanilide) followed by a 
hydrogen-bond donor in beta. For the second family, the linker is derived from the 
N’-ethyl thio-urea moiety. The third family can be described as a polycyclic aromatic 
group (chiefly aryl/heterocycle) linked with an electron-rich group to another 
frequently substituted aryl group. The fourth family combines the characteristics of 
all other molecules with no additional specific features. The chemical structure 
analysis of the inactive compounds showed that both aromatic moieties are 
required for the activity but the structures are not close enough to infer 
structure-activity-relationships, as in each case more than one potential 
pharmacophore is different. Nevertheless, this information will be important for 
further pharmacochemical development of the lead compounds (Supplementary 
Materials, Figure S1).
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3.5 In-silico docking
The general template of all identified hits, with peripheral aromatic rings, showed
some resemblance to the structure of known non nucleoside reverse transcriptase
inhibitors (NNRTI) (Figure 6). In order to test the hypothesis that reverse
transcriptase was indeed the target, we performed in silico docking of six 
compounds representative of the four chemical families in the reverse transcriptase 
structure crystallized with the NNRTI Nevirapine (PDB accession number 1FKP). 
Our data show that they all dock to the same binding pocket as nevirapine (Figure 
7), whereas all other drugs tested for comparison (including antivirals such as
Stavudine, Saquinivir, Acyclovir and Oseltamivir) did not (data not shown). Most 
type I compounds bear a tetrazol group that is related to the structure of 5CITEP 
(1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol- 5-yl)-propenone) (Goldgur et al., 
1999), an inhibitor of the integrase, which was another potential target of our 
screen. To evaluate this possibility, we performed in silico docking of known 
integrase inhibitors to the structure of integrase found in Protein Data Bank (1BL3 
and 1EXQ). However, this attempt was not successful, thereby preventing further
analysis with our hits.
3.6 Inhibitory activity on wild-type and drug-resistant mutant viruses
To demonstrate that the screening assay with pseudotyped lentiviruses was able to 
identify bona fide inhibitors of HIV replication, we tested the six most potent hits on 
different HIV strains. Because chemical structures analysis as well as reverse in
silico docking suggested that the compounds are non-nucleoside reverse 
transcriptase inhibitors, they were tested against wild type HIV virus (NL4.3 strain)
as well as against mutants resistant to either nucleoside inhibitors (AZT, d4T, ddI, 
3TC) or non nucleoside inhibitors (NVP).
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Virus infection was measured in the presence of drugs tested at three different 
concentrations (5 µM, 1 µM and 0.1 µM) and compared to control values obtained 
with either non infected cells or cells infected without drugs (Figure 8). Depending
on the viral strain tested, appropriate control drugs were also added to the 
experiment. As expected, infection of cells with the wild type virus resulted in a 
robust signal that was blocked by the drugs tested in a dose-dependent fashion
(Figure 8A). The mutant viruses showed a different sensitivity to our drugs. Thus,
all compound tested displayed anti-HIV activity against strains resistant to 
nucleosidic antivirals, whereas they were by-and-large ineffective against 
NVP-resistant viruses (Figure 8 E-F). For most of these combinations, estimates for 
IC50 (Table 1 and supplementary material S1 respectively for viral input of MOI 0.02 
and MOI 0.1) were obtained using the freely downloadable package "drc" for "R”. 
An illustration of curve fitting with the L4 model is shown for AZT in the
Supplementary Material (Figure S2). Of note, NC83040 was the most potent
against wild-type and NRTI-resistant strains, and NC87463 exhibited a partial 
inhibition on the K103N nevirapine resistant strain. All IC50 ranged between 
nanomolar to low micromolar, depending on the viral strain used. None of the
tested hits showed a significant inhibition of the highly NVP-resistant strain and, 
therefore, no IC50 could be derived.
4 Discussion
Pseudotyped particles contain the envelope protein from one virus and the core 
from another and mimic some behavior of the wild type viruses (Ma et al., 1999). 
They have been utilized as convenient tools for several applications. If the 
heterologous envelope is the focus of the study, on the one hand, the involvement 
of the surface glycoprotein can be investigated, for example studies on the entry 
mechanism of Ebola (Wool-Lewis & Bates, 1998), Marburg (Chan et al., 2001) or 
hepatitis C (Codran et al., 2006) viruses, the development of sero-diagnostic tests 
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for avian influenza (Nefkens et al., 2007) or SARS (Fukushi et al., 2006), 
vaccination (Bukreyev et al., 2006) or the evaluation of entry inhibitors (Chan et al. 
2006). If the properties of the particles’ core are the focus of the study, on the other 
hand, VSV-G envelope has been commonly used for its wide tropism, with well 
known applications to gene therapy (Baum et al., 2006; Kim et al., 2000). Thus, a 
pseudotype-based assay would permit high-throughput screening in a BSL-2 
contained platform of new drugs inhibiting entry of pathogens that would otherwise 
require a BSL-3/4 facility. The validation of this assay is the first necessary step in 
this direction.
In this study, we have used lentiviral particles pseudotyped with VSV-G to screen 
the library for compounds that would target the post-entry events, i.e. in this case 
lentiviral replication. The present results have, therefore a dual output, validating 
the pseudotype strategy for high-throughput screening in drug discovery and 
identifying new molecules with antiviral activity against HIV-1. The results obtained 
with particles pseudotyped with different viral glycoproteins will be described in a 
separate paper after completion of the relevant screenings. While this manuscript 
was under revision, an article in Chinese describing a similar pseudoparticle-based 
assay appeared in PubMed (Cao and Guo, 2008). Their work was on a much 
smaller scale (only 500 compounds tested), their hits were effective in the 
micromolar range and the specific target was not mentioned.
The assay is robust, flexible and compatible with medium to high throughput. We 
have validated it for inhibitors of HIV replication and identified novel hits belonging 
to four chemical sub-families that appear to be all non nucleoside reverse
transcriptase inhibitors (NNRTi). Confirmatory tests with live viruses showed that 
there was good agreement with pseudotyped particles. In addition, we took 
advantage of naturally occurring viral mutations associated with drug resistance 
and observed that the efficacy of our hits matched the behavior expected for the 
therapeutic class they belong to, viz. NNRTi.
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Screening large libraries can be very cumbersome and expensive. The first solution 
to this problem was to mix the compounds to be tested in pools (usually of 10 
molecules). Despite the evident advantage of compound pooling, the results 
obtained from testing such mixtures necessitate complex deconvolution analysis. 
An elegant alternative method consists of mixing the compounds according to a 
matrix-like layout in an orthogonal cocktail, thereby facilitating the identification of 
the active compounds. The two additional benefits of this strategy are to increase 
the robustness of the assay by testing each compound in duplicate while 
considerably reducing the number of plates in each screen. Although a small scale 
screening of single molecules could have been performed in parallel, we reasoned 
that the most potent compound would be identified also in a cocktail mix.
Nevertheless, we should mention an intrinsic limitation of the orthogonal cocktail 
screen is that if several compounds in one well are either active or toxic, it 
multiplies the pair wise possibilities to trace back and identify the active one. For 
example, during the screening of one batch, 3 pair-wise XY plates showed a 
reduction of luciferase signal in same well F8. In order to investigate which 
compound(s) was (were) responsible for the inhibitory effect, 9 compounds
(corresponding to 32) needed to be tested individually. In this case, only one 
molecule, NC85497, showed true inhibition, whereas 2 were toxic and the 
remaining 6 did not show any effect (Supplementary Material, Figure S3). 
Fortunately such occurrence is relatively rare (owing to the limitation of the cocktail 
to 10 compounds) and all together this strategy still reduces the overall number of 
wells to be tested, compared to single-compound screening, and therefore cost and 
time.
The robustness and sensitivity of this cell-based assay was due to two main factors: 
the cell line used and the selection of the reporter gene. The choice of a cell type is
a critical parameter for assay robustness, biological relevance and reproducibility. 
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HeLa cells have been routinely used for HIV studies (Clavel & Charneau, 1994; 
Morizono & Harada, 1998; Watanabe et al., 2000) and have also the advantage to 
exhibit a relatively high tolerance to DMSO (up to 5% in our assay conditions). An 
appropriate readout was another crucial component. Luminescent reporter genes 
provide highly sensitive, quantitative detection in simple, rapid assay formats. The 
sensitivity of these chemoluminescent detection methodologies typically is several 
orders of magnitude greater than that of conventional colorimetric or fluorometric 
detection methods (Olesen et al. 2000).
Despite the fact that the cell-based assay was designed to identify not only new 
drugs but also new targets for HIV, all our hits seems to belong to the well-studied 
class of NNRTIs. When comparing their chemical structures to other NNRTIs 
described in the literature, compounds from the first family are close to tetrazole 
thioacetanilide derivatives published after completion of our screening (Muraglia et 
al., 2006). These compounds present very good antiviral activity (IC50 at 3-9 nM) 
even against K103N mutant, the most frequently occurring NNRTi drug-resistant 
strains (Soriano & de Mendoza, 2002), as well as an excellent pharmacokinetic
profile in rat (Muraglia et al., 2006). These results illustrate the good quality of the 
hits’ chemical structures. Another important output of the screening is the fact that 
the other three sub-families of the hits present an overall similar structure but yet a 
diverse chemical template. That will help the future pharmacochemical 
development of the compounds, as we can use novel templates with the help of 
more extensive in silico modeling and structure-activity relationship from the 
screening results (viz. chemically related compounds with lower or no activity or 
higher cytotoxicity) as blueprints to derive series through chemical modifications of
the chosen lead compounds. Although all steps of the lentiviral reporter system 
should be equally exposed to our panel of compounds, it is notable that all the 
compounds with antiviral activity found were inhibitors of reverse transcriptase. 
This may simply reflect the compounds present in the library. A systematic bias 
towards inhibitors of reverse transcriptase (rather than, for example inhibitors of 
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integrase) is however unlikely although this can only be formally excluded in future 
screens which include known integrase inhibitors in the chemical library.
In summary, we have developed, optimized and validated a high throughout,
cell-based assay using pseudotype particles. This assay was successfully used for 
the screening of HIV-1 inhibitors and can be easily adapted to screen for entry 
inhibitors using a different surface glycoprotein and an appropriate cell line.
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Figure legends
Figure 1: Schematic representation of the orthogonal cocktail strategy. 100 
“source plates” (depicted in grey) containing a single compound/well were laid out 
in a 10 x 10 grid. Orthogonal cocktails were made by mixing each compound of the 
same well (exemplified by the black dot shown in A1) for either the 10 plates of a 
row (red) or the 10 plates of a column (blue) into “cocktail plates”. Each compound 
is represented twice in 20 mixture plates, each time with 9 different sister 
compounds.
Figure 2: Example of parameter optimization. The kinetic of infection was 
monitored at various cell densities and pseudoparticle (pp) dilutions as specified. 
Optimal results were achieved for all conditions between 48-72 h post-infection. 
Signal is expressed in Relative Luminescence Unit (RLU).
Figure 3: Example of primary screening output. 8000 compounds were 
screened in 10-compounds orthogonal cocktail plates. Horizontal lines correspond 
to different cut-off limits calculated from the average (m) and standard deviation 
(SD) of samples. The activity of tested compounds was considered inhibitory when 
both values from Y (blue) and X (red) plates fell below the pre-defined cut-off 
(m-2SD). Control wells contained 0.1mM AZT (grey) or 2% DMSO (yellow) alone. 
Colored box shows the MTT cytotoxicity results subsequently obtained with the 
individual molecules: green: non toxic (<10% inhibition growth in MTT assay);
orange: marginally toxic (between 10 to 30% inhibition growth), red: toxic (>50% 
inhibition growth). Three of the compounds more thoroughly studied are identified 
by their library code name. Results are expressed in Relative Luminescence Unit 
(RLU).
Figure 4: Selectivity of inhibition. The specificity of post-entry inhibition of HIV 
was tested to exclude an effect of the VSV-G envelope (diamonds; cf. to HxB2, 
squares) or of the reporter gene luciferase (diamonds; cf. to GFP, triangles). As an 
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additional control we found that the drug did not inhibit the replication of the Semliki 
Forest alphavirus (open circles). Other hits as well as AZT gave similar profiles 
(data not shown). The plot shows the percentage inhibition of the luciferase signal 
by compound NC83040 as a function of the drug concentration (expressed as the 
logarithm of molarity). Maximum (100%) and minimum (0%) values were recorded 
in the absence of pseudotyped particles and in the absence of the drug, 
respectively.
Figure 5: Time of addition study. Drugs were added at different time post 
infection. All drugs were ineffective when added 5 hrs after infection with a time 
course similar to AZT.
Figure 6: Classification of the hits. All the hits can be derived from a general 
template; four major sub-families were identified from a detailed analysis of their 
chemical structures.
Figure 7: In silico docking. The model illustrates a portion of the crystal structure 
of reverse transcriptase in its bound conformation to the NNRTi Nevirapine (PDB 
1FKP). All six drugs tested docked to the same binding pocket. Modelization 
realized with Argulab software.
Figure 8: Inhibition of live virus replication in cultured cells. Viral replication 
was monitored 72 hrs post-infection (viral input 1 ng) by measuring ß-galactosidase 
activity in a colorimetric CPRG assay either in the presence or absence of drugs 
tested at three different concentrations: 5 µM (white bars), 1 µM (grey bars) and 0.1 
µM (black bars). Six different strains of viruses were used: wild type NL4.3 (A); and 
different mutants resistant to the following drugs (B) AZT (NL4.3-XCS 41-215); (C) 
AZT, d4T, ddI (NL4.3-XCS MDR 151); (D) 3TC (NL4.3 XCS M184V); (E) NVP 
(NL4.3-XCS K103N) and (F) very resistant to NVP (NL 4.3 XCS 188L-190A). 
Percentage of inhibition was calculated from values obtained in wells infected in the 
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absence of drugs (no drug), corrected for background noise (non infected cells, NI). 
Results are shown as means  SD of three observations.
Table 1: Estimation of IC50 obtained by inhibition of live virus. Concentrations 
(nM) resulting in fifty percent inhibition of viral infection were derived for different 
strains of NL4.3 XCS (viral input 1 ng p24, MOI ~0.02) in presence of increasing 
drug concentrations (100 nM, 1 µM and 5 µM). Values were estimated after fitting 
the inhibition data with the package "drc". ND: not determined; R: drug resistance 
(no inhibition of viral replication up to 5 µM). Results are shown as means ± SD of 
six samples from two independent experiments (triplicate measurements).
Table 2: Estimation of IC50 obtained by inhibition of pseudoparticles. The 
concentrations (nM) resulting in 50% inhibition of viral infection were calculated for 
the following different pseudotypes HIV-HxB2-HIV(Luc), VSV-G-HIV(Luc) and
VSVG-HIV(GFP) (as mentioned in the Results, section 3.4). Values were fitted 
using the Hill equation and standard deviations were calculated from values 
obtained in quadruplicate from a single experiment.
Supplementary Materials:
Figure S1: Chemical structure of active and related inactive compounds belonging 
to the four chemical sub-families depicted in Figure 6.
Figure S2: Estimation of IC50 by sigmoid curve fitting. The plot illustrates, for 
the different strain of viruses, the dose-dependent inhibition of viral infection by AZT 
fitted using model L4 the freely downloadable package "drc" for "R” (see Materials 
and Methods). Experimental conditions were as in Figure 10. The response was 
measured as β-galactosidase activity in a CPRG colorimetric assay. Control values 
(no inhibition) correspond to the signal recorded in absence of drugs; the OD 
recorded in the absence of viruses is plotted as a 1 mM drug concentration 
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(corresponding to maximal inhibition).
Figure S3: Illustration of the potential complexity linked to the unambiguous 
identification of an active compound using the orthogonal cocktail strategy.
In order to investigate which compound(s) was (were) responsible for the inhibitory 
effect, 9 compounds (corresponding to 32) needed to be tested individually. In this 
case, only one molecule, NC85497, showed true inhibition, whereas 2 were toxic 
and the remaining 6 did not show any effect
Table S2: Estimation of IC50 obtained by inhibition of live virus (viral input:
5ng of p24). Concentrations (nM) resulting in fifty percent inhibition of viral infection 
were derived for different strains of NL4.3 XCS (viral input 5 ng p24, MOI ~0.1) in
presence of increasing drug concentrations (100 nM, 1 µM and 5 µM). Values were 
estimated after fitting the inhibition data with the package "drc". ND: not determined; 
T: cytotoxicity by cytopathic effect (CPE); R: drug resistance (no inhibition of viral 
replication up to 5 µM). Results are shown as means ± SD of triplicate 
measurements.
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Table 1:
Virus strain (drug resistance)
WT 41-215 MDR 151 M184V K103N 188L-190A
IC50 (nM)
- (AZT) (AZT, d4T, ddI) (3TC) (NVP) (NVP)
NC80937 801±558 533±306 1596±89 662±341 2141±352 R
NC83040 172±521 239±24 786±445 138±42 1534±392 R
NC85497 418±239 331±78 1284±77 382±85 1043±127 R
NC86077 800±116 914±107 864±79 631±171 R R
NC87463 447±136 137±33 751±59 206±32 789±71 R
NC88104 1117±183 400±184 1573±346 666±156 R R
AZT 43±11 1120±329 R 21±15 63±63 113±30
3TC ND ND ND R 330±67 1469±535
C
o
m
p
o
un
ds
 t
es
te
d
NVP 28±2 ND ND 44±13 2566±520 R
Table 2:
Pseudoparticle type
IC50 (nM) VSV-G-HIV(Luc) HxB2-HIV(Luc) VSV-G-HIV(GFP)
NC80937 201 ± 64 274 ± 87 584 ± 126
NC83040 105 ± 7 141 ± 24 280 ± 16
NC85497 119 ± 44 299 ± 52 758 ± 16
NC86077 202 ± 54 289 ± 66 1130 ± 151
NC87463 92 ± 7 83 ± 46 183 ± 45
NC88104 207 ± 15 263 ± 126 730 ± 131C
o
m
p
o
un
ds
 t
es
te
d
AZT 3 ± 0.5 4 ± 1 1.3 ± 0.1
Table S1
Virus strain (drug resistance)
WT 41-215 MDR 151 M184V K103N 188L-190A
IC50 (nM)
- (AZT) (AZT, d4T, ddI) (3TC) (NVP) (NVP)
NC80937 815±1098 413±155 1446±204 468±146 3731±516 R
NC83040 69±20 384±1241 803±21 172±61 R R
NC85497 T 345±61 1147±67 377±598 1230±650 R
NC86077 T 870±90 885±137 552±132 R R
NC87463 T 154±136 921±35 211±48 331±103 R
NC88104 T 1105±66 1579±124 677±212 R R
AZT 48±6 1306±222 R 43±16 43±13 74±16
3TC ND ND ND R 6±5 2193±331
C
o
m
p
o
un
ds
 t
es
te
d
NVP ND ND ND 63±20 5678±1724 R
Table(s)
